Celgene Co. (CELG) Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC reduced its holdings in Celgene Co. (NASDAQ:CELG) by 17.7% in the third quarter, HoldingsChannel reports. The firm owned 30,800 shares of the biopharmaceutical company’s stock after selling 6,623 shares during the period. Sterling Capital Management LLC’s holdings in Celgene were worth $4,491,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. increased its holdings in Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. increased its holdings in Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. Jennison Associates LLC increased its holdings in Celgene by 11.5% in the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after purchasing an additional 1,546,673 shares in the last quarter. FMR LLC increased its holdings in Celgene by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after purchasing an additional 697,250 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Celgene by 3.3% in the second quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after purchasing an additional 349,974 shares in the last quarter. Institutional investors and hedge funds own 78.93% of the company’s stock.

A number of brokerages have commented on CELG. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective for the company in a research note on Thursday, January 25th. Mizuho set a $128.00 price objective on Celgene and gave the company a “buy” rating in a research note on Tuesday, December 26th. William Blair reissued an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. BTIG Research reissued a “hold” rating on shares of Celgene in a research note on Tuesday, January 23rd. Finally, BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $130.35.

Celgene Co. (NASDAQ CELG) opened at $93.74 on Tuesday. The stock has a market capitalization of $78,574.23, a P/E ratio of 26.18, a P/E/G ratio of 0.71 and a beta of 1.49. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 1 year low of $93.63 and a 1 year high of $147.17.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 64.14% and a net margin of 22.38%. Celgene’s quarterly revenue was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.61 earnings per share. research analysts forecast that Celgene Co. will post 7.68 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2018/02/06/celgene-co-celg-shares-sold-by-sterling-capital-management-llc.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit